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Background. Nocturnal hemodialysis is a novel form of dialy-
sis where patients perform dialysis 6 nights per week while they
sleep. Multiple publications report significant improvements in
selected clinical outcomes, although the strength of these results
is limited by shortcomings in study design. A systematic review
of the current available literature was undertaken to examine
the effect of nocturnal hemodialysis on key health outcomes.
Methods. An inclusive search of medical databases was un-
dertaken to identify all nocturnal hemodialysis studies. These
results were manually reviewed for relevance to nocturnal
hemodialysis and its impact on the following predefined health
outcomes: blood pressure control, left ventricular hypertrophy,
anemia, mineral metabolism, and health related quality of life.
Case reports, short-term studies (<4 weeks), studies without
comparator groups, and studies not reporting data in a quantita-
tive fashion were excluded. The results of the remaining studies
were reported in tabular format.
Results. Of the initial 270 studies identified, only 14 met in-
clusion/exclusion criteria. No studies examining the impact of
nocturnal hemodialysis on mortality were identified. All studies
reported improved blood pressure control after conversion to
nocturnal hemodialysis. Data regarding the other health out-
comes of interest revealed mixed results.
Conclusion. Nocturnal hemodialysis is a potential alternative
to conventional intermittent hemodialysis. Before significant
resources are invested in initiating nocturnal hemodialysis pro-
grams, further data on mortality and cardiovascular morbidity,
preferably from randomized clinical trials, are required.
The first report of daily dialysis was in 1969 by De-
Palma et al, who described outcomes in 7 patients re-
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ceiving dialysis 5 times per week, 4 to 5 hours per ses-
sion [1]. These patients were selected for daily therapy
mostly based on severe intradialytic hypotension; this
problem resolved, and all patients reported improved ap-
petite, weight gain, and general well-being. Other groups
experimented with daily dialysis in the 1970s, and al-
though clinical outcomes in selected patients appeared
favorable, these programs were abandoned due to fund-
ing difficulties and the resource intensity of the treatment
[2, 3].
The use of slow daily nocturnal hemodialysis (NHD)
was revolutionized by a group in Toronto led by Robert
Uldall and Andreas Pierratos. This program, initiated in
1994, has reported impressive results for selected patients
who were treated with long, slow, overnight hemodialy-
sis at home [4]. Subsequently, enthusiasm for NHD has
been growing among renal programs in North America
and Europe. In fact, many centers are examining the fea-
sibility and attempting to obtain funding so that NHD can
be routinely offered to patients requiring dialysis. This en-
thusiasm must be tempered by lack of randomized trials
investigating the impact of NHD on clinical outcomes. In
fact, existing studies on NHD have been small, have been
done in highly select ESRD patients, and often present
conflicting results. Given the substantial resources that
would be required to initiate and maintain a NHD pro-
gram, a critical evaluation of the available evidence is
necessary to determine its potential role in the treatment
of end-stage renal disease.
We performed a qualitative systematic review to gather
and summarize all current evidence available on the ef-
fect of nocturnal dialysis on several key health parame-
ters, including: (1) left ventricular hypertrophy and blood
pressure control; (2) anemia; (3) calcium-phosphate bal-
ance; and (4) health-related quality of life (HRQOL).
The study hypothesis was that nocturnal hemodialysis, in
comparison to conventional hemodialysis, would have no
impact on these key health parameters.
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Database and reference
list search
N = 270 papers
Relevant to NHD
N = 71
Excluded
N = 57
Included
N = 14
Thrice weekly : N = 8
Case reports : N = 2
Outcomes not considered
in this paper : N = 18
Reviews, editorials and
previously published
subsets : N = 29
Fig. 1. Flow diagram documenting inclusion
and exclusion of nocturnal hemodialysis stud-
ies.
Review methods
A thorough review of available literature was under-
taken. Inclusive databases were identified and included:
Medline via Ovid (1966 to week 4 of July 2003), Em-
base via Ovid (1980 to week 4 of July 2003), Cochrane
databases via Ovid, BioAbstracts via Silverplatter, Cinahl
via Ovid, DARE via Ovid, Health Technology Assess-
ment Database via York University, and Proceedings
First via USC website. The search terms selected were
“nocturnal” or “nightly” as keywords in titles or ab-
stracts, and “dialysis,” “hemodialysis” or “renal dialysis”
as MESH or keywords. Non-English studies were in-
cluded. Determination of search inclusiveness was judged
by comparing the search results to recently published re-
views. Additional studies were identified by review of ref-
erence lists, as well as communication with experts in the
field. All abstracts were then manually reviewed by 2 in-
dependent reviewers (M.W. and B.M.) for relevancy to
the study topic. Papers were included if they dealt with
nocturnal hemodialysis (as defined by dialysis occurring
at least 5 nights per week and at least 6 hours per night),
reported on 1 of the 4 predefined outcomes of interest,
and reported data in a quantitative fashion. Case reports
(including studies with fewer than 5 patients), editori-
als, and review papers were excluded, as were short-term
studies (i.e., less than 4 weeks) or studies that did not in-
clude a comparator group (i.e., case controls or pre-post
within patient comparison). Multiple publications on sin-
gle data sets were noted, and only the most recent papers
were included, provided prior publications did not con-
tain novel data. Efforts were made to contact authors
of papers when concern about duplicate publication ex-
isted. Disagreements between reviewers were settled by a
third reviewer (B.C.), and the remaining relevant papers
were collected. Data on the 4 primary dialysis-related
morbidities were manually extracted into a database with
accompanying study design data, and were then distilled
into individual tables for each of the selected outcomes
studied. Due to the observational nature of the included
studies, meta-analysis was not performed.
Details of the included and excluded studies
The initial literature search returned 270 papers and
abstracts (Fig. 1), 71 of which were found to be relevant to
nocturnal dialysis. Of these, 7 papers and 1 abstract were
based on thrice weekly NHD [5–11], 2 papers were case
reports [12, 13], 16 papers and 2 abstracts did not report
information on the clinical end points of interest [14–29],
and 29 were either reviews, editorials, solely qualitative
in nature, or contained previously published subsets of
data [30–58]. The remaining 10 papers and 4 abstracts
were included in the systematic review [59–68, abstracts;
Brissenden J et al, J Am Soc Nephrol 9:168A, 1998; Chan
C et al, J Am Soc Nephrol 13:60A, 2002; Chan C et al,
J Am Soc Nephrol 14:498A, 2003; Lorch J, Pollak V, J
Am Soc Nephrol 14:232A, 2003], although only part of
the data (i.e., that dealing with longer-term outcomes of
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Table 1. Study design of included papers
Comparison/
Author Study design Study duration Population Treatment group control group
Musci [65] Prospective pre/post 6 months 7 IHD patients switched
to NHD
8 to 10 hours of
nocturnal 6 to
7×/week
Baseline measurement
prior to starting NHD
Brissenden J et al, J
Am Soc Nephrol
9:168A, 1998
Prospective pre/post
(abstract)
3 months 18 IHD patients
switched to NHD
8 hours of nocturnal
6×/week
Baseline measurement
prior to starting NHD
Lockridge [63] Prospective pre/post 6 months 5 IHD patients switched
to NHD
7–9 hours of nocturnal
6×/week
Baseline measurement
prior to starting NHD
McPhatter [64] Prospective pre/post 18 months 11 patients switched
from PD or IHD to
NHD
8 hours of nocturnal
6×/week
Baseline measurements
prior to starting NHD
Williams [68] Prospective pre/post 6 to 8 weeks 5 nondiabetic IHD
patients switched to
NHD (3 followed >4
weeks)
8 hours of nocturnal
6×/week
Baseline measurements
prior to starting NHD
Chan [59] Prospective pre/post Average 3.2 ± 2.1
years
6 stable IHD patients
with reduced ejection
fraction switched to
NHD
8–10 hours of nocturnal
6×/week
Baseline measurement
during 4 weeks prior
to starting NHD
Chan [60] Prospective
nonrandomized
pre/post with IHD
control
Average 3.4 years
for NHD and
2.8 years for
IHD controls
28 patients converted
from IHD to NHD;
13 IHD controls
8–10 hours of nocturnal
6×/week
Baseline measurements
prior to starting
NHD; 13 IHD
controls
Chan C et al, J Am
Soc Nephrol
13:60A, 2002
Prospective pre/post
(abstract)
2 months 15 patients converted
from IHD to NHD
8 hours of nocturnal
6×/week
Baseline measurements
prior to starting NHD
Chan C et al, J Am
Soc Nephrol
14:498A, 2003
Retrospective
cohort study
(abstract)
12 months 63 patients converted
from IHD to NHD;
31 IHD controls
6–8 hours of nocturnal
5–6×/week
Baseline measurements
prior to starting
NHD; 31 IHD
controls
London Quotidian
HD Group
Prospective pre/post
with case control
12 patients converted
from IHD to NHD; 22
IHD controls (except
Nesrallah—13 IHD to
NHD and 19 matched
IHD controls)
8 hours of nocturnal
6×/week
Baseline measurements
prior to starting
NHD; 22 IHD
controls
Lindsay [62] Calcium-phosphate Up to 30 months
Heidenheim [61] Quality of life Up to 18 months
Nesrallah [66] Blood pressure Up to 18 months
Rao [67] Anemia Up to 18 months
Lorch J, Pollak V,
J Am Soc
Nephrol
14:232A, 2003
Prospective pre/post
(abstract)
2–23 months 5 patients converted
from IHD to NHD
Mean 4.8×/week Baseline measurement
prior to starting NHD
NHD) was considered from 1 study [65]. Three of these
papers presented data only in a semiquantitative form
[63, 68, abstract; Lorch J, Pollak V, J Am Soc Nephrol
232A, 2003]. These data were included in the body of the
text below, but were not summarized within the tables.
For a complete list of abstracts that were excluded, please
contact the corresponding author.
RESULTS
Relevant papers
Fourteen reports (Table 1) concerning the key outcome
measures were identified. These comprised work from the
groups in London (Canada), Toronto (Canada), Lynch-
burg (VA, USA), and Rochester (MN, USA). All iden-
tified studies were either pre-post within-patient com-
parison or case control studies. Average follow-up times
ranged from 6 weeks to 3.4 years. Study sample sizes
ranged from 5 to 63 NHD patients. There were large
differences in reporting styles for any given clinical pa-
rameter. There were no randomized trials identified. No
comparative data on survival or the occurrence of cardiac
events were found. Two studies included a short daily dial-
ysis comparator group in addition to the conventional and
nocturnal groups [23, 68]. In these instances, data from
patients receiving short daily dialysis were excluded.
Blood pressure control and left ventricular hypertrophy
Four studies were identified in which blood pressure
control parameters were the primary or secondary out-
come measures (Table 2) [59, 60, 66, abstract; Chan C
et al, J Am Soc Nephrol 13:60A, 2002]. Of these, 3 papers
came from the Toronto group [59, 60, abstract; Chan C
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Table 2. Impact of NHD on blood pressure and left ventricular hypertrophy
Author Blood pressure mm Hg Antihypertensive use LV mass index
Chan [59] SBP 138 ± 10 to 120 ± 9 (P 0.04) 2.2 to 0.7 cardiovascular medications
(P 0.02)
180 ± 54 g/m2 to 143 ± 45 (P > 0.05)
DBP 80 ± 9 to 69 ± 7 (P > 0.05)
MAP 99 ± 6 to 86 ± 7 (P 0.01)
Chan [60] SBP 146 ± 20 to 122 ± 13 for NHD
(P < 0.001 within NHD patients)
1.8 to 0.3 medications for NHD (P <
0.001 within NHD patients)
147 ± 42 g/m2 to 114 ± 40 g/m2 for
NHD (P 0.004 within NHD
patients)DBP 84 ± 15 to 74 ± 12 (P < 0.05
within NHD patients)
1.5 to 1.5 medications for IHD (P > 0.05
for comparison of NHD and IHD
controls)MAP 104 ± 16 to 90 ± 11 (P < 0.05
within NHD patients
142 ± 33 g/m2 to 150 ± 56 for IHD (P <
0.05 for comparison of NHD and IHD
controls)No difference for comparison of
NHD and IHD controls
Chan C et al, J Am
Soc Nephrol
13:60A, 2002
24 hour SBP 134 ± 17 to 120 ± 8
(P < 0.05)
2.4 to 0.1 medications (P < 0.05) Not reported
24 hour DBP 85 ± 11 to 75 ± 9
(P < 0.05)
Nesrallah [66] NHD MAP 117.1 ± 22.6 to 97.1 ± 8.4
(P < 0.03)
NHD 3.3-fold reduction in tablets per
day, 8/13 decreased or discontinued
medications, decrease in
dose-weighted score 0.202 (P < 0.05)
Not reported
Control MAP 105.8 ± 12.8 to
104.5 ± 9.4
Control 1.4-fold increase in tablets per
day, 1/10 decreased or discontinued
medications
et al, J Am Soc Nephrol 13:60A, 2002]. Personal commu-
nication with the first author verified that data in each pa-
per was novel. All studies used a case control or pre-post
design. Nessrallah et al [66] measured blood pressure in
the predialysis period, Chan et al [59] took measurements
at clinic visits, and a later study by the same group used
24-hour ambulatory blood pressure measurements [ab-
stract; Chan C et al, J Am Soc Nephrol 13:60A, 2002].
Another report did not specify when blood pressure
measurements were obtained [60]. Three papers report
systolic blood pressures, and all of them reported a signifi-
cant reduction in systolic blood pressure by the end of the
study period in the NHD [59, 60, abstract; Chan C et al,
J Am Soc Nephrol 13:60A, 2002]. Diastolic blood pressure
was reported in 3 studies, revealing a significant reduction
in 2 studies [60, abstract; Chan C et al, J Am Soc Nephrol
13:60A, 2002] in NHD patients, and a trend toward reduc-
tion in the third [59]. Two studies reported mean arterial
blood pressure (MAP), and this was reported to be sig-
nificantly lower in the NHD group [60, 66]. These same 2
reports included a comparison to matched IHD controls.
Neither of these found a significant difference in blood
pressure between the NHD and IHD patient groups.
Antihypertensive medication use was significantly re-
duced following institution of NHD in all studies in the
nocturnal group [59, 60, 66, abstract; Chan C et al, J Am
Soc Nephrol 13:60A, 2002]. Extracellular fluid volume did
not appear to change between conventional and noctur-
nal groups in the 3 studies in which it was reported [59,
60, 66].
Three other papers reported on blood pressure in 5
NHD patients although the data were only reported in
a semiquantitative fashion. Williams et al [68] reported
blood pressure control was achieved with fewer antihy-
pertensives and a trend toward reduction in predialysis
MAP by the end of 8 weeks on NHD for 4 patients. Lorch
and Pollak [abstract; Lorch J, Pollak V, J Am Soc Nephrol
14:232A, 2003] reported improved blood pressure control
in 2 of 5 patients converted to NHD, and Lockridge et al
[63] showed improved blood pressure control with fewer
medications in 4 out of 5 patients.
Left ventricular hypertrophy was assessed as a primary
outcome in 2 papers (Table 2) [59, 60]. One study, in NHD
patients without congestive heart failure, showed a signif-
icant reduction in LV mass after 12 months of NHD; LV
mass was also reduced compared to a matched IHD pop-
ulation [60]. The other study, in patients with congestive
heart failure, showed a nonsignificant reduction in LV
mass, and a significant improvement in ejection fraction
following conversion to NHD [59].
Anemia
Three studies were identified that reported changes in
hemoglobin as an outcome (Table 3) [59, 67, abstract;
Chan C et al, J Am Soc Nephrol 14:498A, 2003]. All 3 stud-
ies noted a significant increase in hemoglobin for patients
after conversion to NHD. However, there was no signifi-
cant difference noted between the IHD control group and
the NHD group in Rao et al [67]. Another paper by Chan
et al [60], which included a subset of patients from a later
publication, also reported no difference in hemoglobin
when comparing the NHD group to a matched IHD con-
trol group. However, this same study noted a significant
increase in hemoglobin in the NHD patients after con-
version from conventional to nocturnal hemodialysis.
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Table 3. Impact of NHD on hemoglobin and erythropoietin use
Author Hemoglobin g/dL Erythropoietin dose
Chan [59] 11.6 ± 1.0 to 13.1 ± 1.4 (P = 0.05) Not reported
Chan C et al, J Am
Soc Nephrol
14:498A, 2003
IHD: 11.0 ± 0.2 to 11.5 ± 0.2 (12 mos), (P > 0.05) IHD: 8258 ± 1166 to 8607 ± 1087 u/wk (12 mos) (P > 0.05)
NHD: 11.5 ± 0.2 to 12.3 ± 0.2 g/L (12 mos) (P = 0.03) NHD: 10405 ± 1388 to 7652 ± 1107 u/wk (12 mos) (P =
0.03)
Rao [67] IHD: 11.79 ± 1.92 to 11.49 ± 0.74 IHD 0.79 ± 0.78 U/wk/kg/g/L to 0.63 ± 0.45
NHD: 10.95 ± 1.79 to 11.94 ± 1.66 (P < 0.05 within
NHD patients; P > 0.05 for comparison of NHD and
IHD controls)
NHD 1.36 ± 1.49 U/wk/kg/g/L to 1.76 ± 1.78 (P > 0.05
within NHD patients and for comparison of NHD and
IHD controls)
Table 4. Impact of NHD on mineral metabolism
Author PTH Calcium Phosphate Ca×PO4 Meds
Musci [65] 49.7 ± 26.7 pmol/L to
19.0 ± 23.9 (not
statistically different)
9.6 ± 0.8 to 9.6 ± 1.0
mg/dL (not
statistically different)
Serum PO4 control: 6.50
± 1.55 mg/dL
Not reported Calcium carbonate: 2400
(1400 to 4500) mg/d to 0
(0 to 1500) mg/d (P <
0.05)
Serum PO4 NHD: 4.02 ±
0.62 mg/dL (P < 0.01)
Chan [60] IHD: 40.7 ± 36.2 pmol/L
to 40.1 ± 30.0
Not reported Not reported Not reported Not reported
NHD: 34.9 ± 55.0 to 16.6
± 24.3
(P > 0.05 within NHD
patients and for
comparison of NHD
and IHD controls)
Lindsay [62] IHD: 286.7 ± 252.5
pg/mL to 76.5 ± 8.7
IHD: 9.9 ± 0.8 mg/dL to
9.9 ± 1.0
Predialysis IHD: 5.7 ±
1.7 mg/dL to 5.3 ± 1.3
IHD: 57.3 ± 18.9
mg2/dL2 to 52.5 ± 12
Calcium carbonate
phosphate binder dose
NHD: 235.3 ± 262.7
pg/mL to 171.9 ±
173.2
NHD: 10.1 ± 1.0 mg/dL
to 10.2 ± 0.1
Predialysis NHD: 5.0 ±
1.5 mg/dL to 3.9 ± 1.1
NHD: 50.6 ± 14.9
mg2/dL2 to 38.1 ±
11.5
IHD: 2823 ± 1099 mg/d to
3101 ± 2872 mg/d
(P > 0.05 within NHD
patients and for
comparison of NHD
and IHD controls)
(P > 0.05 within NHD
patients and for
comparison of NHD
and IHD controls)
(P > 0.05 for all within
NHD patients and
between group
comparisons)
(P < 0.05 for
comparison of NHD
and IHD controls; P
> 0.05 within NHD
patients)
NHD: 2589 ± 2157 mg/d
to 900 ± 1273
(P > 0.05 for within NHD
patients and between
group comparisons)
Two papers also examined the impact of NHD on ery-
thropoietin dose (Table 3) [67, abstract; Chan C et al,
J Am Soc Nephrol 14:498A, 2003]. Chan et al noted a
significant reduction in weekly dose after conversion to
NHD, with no change in the IHD control group’s dose.
The second study found no significant reduction in dose
after conversion to NHD, although there was a trend to-
ward reduction [67]. In both studies, the IHD control
group started with a lower average weekly erythropoietin
dose. Additionally, Lockridge et al [63] reported that the
hemoglobin of 4 out of 5 patients could be maintained on
lower doses of erythropoietin.
Calcium-phosphate metabolism
Three studies were identified that examined the effects
of NHD on calcium and phosphate balance (Table 4) [60,
62, 65]. None of these studies noted a significant differ-
ence in serum PTH after conversion to NHD, and of the 2
studies that had IHD control groups, neither study noted
a significant difference in serum PTH between groups. In
the 2 papers reporting serum calcium data, no significant
difference was noted after conversion to NHD [62, 65].
Two studies examined the effect of NHD on serum phos-
phate. One study noted a significant reduction in serum
phosphate after 6 months of NHD [65]. The second study
noted no significant reduction in serum phosphate after
30 months of NHD, and noted no differences between
NHD patients and IHD controls with respect to serum
phosphate [62]. In the 2 studies that examined the im-
pact of NHD on phosphate binding medications, only 1
study noted a significant reduction in calcium carbonate
[65]. The remaining study found a nonsignificant trend to-
ward reduction in phosphate binding medications in the
NHD group [62]. The study by Williams et al showed a
significant decrease in mean phosphate (P = 0.04) and an
increase in serum calcium (P = 0.031), while PTH showed
a trend toward reduction that was nonsignificant [68].
Lockridge et al [63] also showed that phosphate binders
could be discontinued in all patients within 3 months of
starting NHD, and most required phosphate supplemen-
tation in dialysate to maintain a normal serum phosphate
level. In the London study, calcium phosphate product
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was reported; a significant reduction was noted for the
NHD patients compared with the IHD control group [62].
However, no significant difference was observed between
the initiation of NHD and the end of the study.
Health-related quality of life
Studies that reported health-related quality of life out-
comes had no common reporting method, and full de-
tails of the quality-of-life assessment tools/scores were
not available in any study [61, 63, 64, abstract; Brissenden
J et al, J Am Soc Nephrol 9:168A, 1998]. Brissenden ex-
amined the effect of NHD on Sickness Impact Profile
(SIP; composed of 12 subscales with lower scores indi-
cating improvement) [69] and SF-36 scores (composed
of 8 subscales from 0 to 100 with higher scores indicat-
ing improvement) [70]. Only subscale scores for which a
statistically significant improvement or trend toward im-
provement were reported. The SIP showed an improve-
ment in the total score (14 to 9.5; P = 0.03), eating (14.2 to
3.7; P = 0.003), and household management (25.6 to 15;
P = 0.01). Trend to improvement was seen in ambulation
(17.2 to 11.1; P = 0.07), mobility (3.9 to 2.9; P = 0.08),
and social interaction (16.4 to 11.4; P = 0.07). The SF-36
showed improvements in social functioning (54.2 to 79.2;
P = 0.006), physical functioning (60.6 to 69; P = 0.008),
and role-physical (39.2 to 36.1; P = 0.05). General health
(39.6 to 46.0; P = 0.14) and vitality (46.4 to 56.5; P =
0.13) showed a trend to improvement. An improvement
(8.5 to 6.0; P = 0.02) was also noted in the Beck De-
pression Inventory score. McPhatter et al [64] published
the SF-36 portion of the CHOICE questionnaire results
applied preinitiation of NHD and 3 and 6 months’ postini-
tiation. The CHOICE questionnaire is an ESRD-specific
health-related quality-of-life assessment tool composed
of 21 domains containing 83 items. Higher scores indicate
a better quality of life than lower scores. P values were
not reported, but improvements were noted in 5 patients:
physical functioning 59 to 85, pain index 45 to 85, vitality
40 to 75, role-emotion 45 to 94, social functioning 46 to
87, health perceptions 47 to 70, and role-physical 31 to 85.
Scores were not improved in the mental health domain
of the SF-36 component of the CHOICE questionnaire.
Heidenheim et al [61] published the results of the Lon-
don group, which used the Renal Disease Specific Quality
of Life indicators, SF-36, and time trade-off scores. An
initial improvement (at month 9) in the Renal Disease
Specific Quality of Life indicators was noted after con-
version to nocturnal hemodialysis, although no difference
was noted 18 months after conversion to NHD, or when
NHD patients were compared to the IHD control group.
Moreover, the physical and mental composite scores of
the SF-36 did not change after conversion to NHD, or
when compared to the IHD control group. When the time
trade-off method, which represents a single global mea-
sure of HRQOL, was used, the NHD group improved
from 0.23 ± 0.24 to 0.78 ± 0.17 (P < 0.05). However, when
time trade-off scores were compared between NHD pa-
tients (0.78 ± 0.17) and the matched IHD comparison
group (0.70 ± 0.27), no difference was noted. Lockridge
et al [63] reported data on 5 patients at 6 months after
starting NHD, showing a greater than 45% improvement
in 7 domains of the SF-36, and in 6 of these, at least an
85% improvement.
DISCUSSION
To our knowledge, this represents the first systematic
review of health-related outcomes in nocturnal hemodial-
ysis. An inclusive search strategy was employed to enable
potential capture of nonpublished data, as well as studies
published in well-known nephrology journals. While in-
dividual studies have generally been supportive of NHD
over IHD, the magnitude of improvement in specific pa-
rameters has varied markedly between studies.
The current literature suggests a benefit of NHD in sev-
eral areas. There is general agreement that systolic, mean
arterial, and diastolic pressure are improved after con-
version to NHD, and that fewer antihypertensives are re-
quired to achieve this control. Interpretation of this data,
however, is complicated by a lack of difference between
NHD patients after conversion and their IHD controls
[60, 66]. With regard to the regression of LVH, results
are similarly mixed, even within a single center’s experi-
ence [59, 60].
Regarding the impact of NHD on anemia, a consis-
tent improvement in hemoglobin is seen after conver-
sion to NHD, although no difference has been noted
when compared to IHD controls [59, 67, abstract; Chan
C et al, J Am Soc Nephrol 14:498A, 2003]. Interpreting
this data is difficult as only Rao et al [67] reported a
target hemoglobin level. Without a prespecified target,
improvements in hemoglobin control may simply reflect
improved vigilance in the NHD group. Complicating this
data even further is the inequality of hemoglobin levels at
baseline. As seen in Rao et al [67], the IHD control group
trended toward a higher baseline hemoglobin level and
lower baseline mean erythropoietin dose than the NHD
group. The decrease in erythropoietin use after conver-
sion to NHD also remains to be clarified with only one
study reporting a significant reduction in dose [abstract;
Chan C et al, J Am Soc Nephrol 14:498A, 2003].
In the area of mineral metabolism there is no clear
consensus on the impact of NHD on serum calcium,
phosphate, or PTH, although some studies reported a sig-
nificant reduction in the use of phosphate-binding medi-
cations. The interpretation of these results is complicated
given the frequent need to liberalize phosphate intake,
and the addition to phosphate to the dialysate of some
patients treated with NHD. Unfortunately, most studies
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did not quantify phosphate intake, and dietary journals
were not reported.
Health-related quality-of-life measures appear to im-
prove after conversion to NHD, although the degree and
clinical significance of improvements in quality of life
have been variable. For example, some small studies re-
ported a greater than 85% improvement in selected do-
mains of quality of life, while others noted only minimal
improvement [63, 64].
One of the strengths of this study is that we followed
contemporary guidelines for the conduct and reporting of
meta-analyses of observational studies [71]. The strength
of our conclusions, however, is limited by the existing lit-
erature. We were unable to find any data on hard clinical
outcomes associated with NHD, including survival and
cardiovascular end points. The numbers of patients in all
studies was quite limited, reducing their statistical power.
In addition, differences in the reporting styles for some
outcomes make direct comparison of studies difficult. Fi-
nally, the specific mechanisms through which NHD may
actually improve health outcomes also remain uncertain.
Several potential limitations of this study should be
considered. First, for the outcomes considered, there is
little potential for summary analyses, given the nature
of the data. Second, as the health outcomes investigated
were chosen a priori to the literature review, several clin-
ically important outcomes were not reviewed, including
nutrition, sleep-related disorders, dialysis adequacy, and
access complications. It is important to note that the lack
of standardization in reporting on these variables makes
comparing their outcomes difficult. Third, in the time
subsequent to the search for papers to be included in
this review, more data have become available regarding
NHD. This is an inherent limitation of systematic reviews.
For example, subsequent to our search strategy, Chan et
al have published results of a mechanistic analysis per-
formed to elucidate the biology underlying the blood
pressure reduction seen in NHD [72], and McFarlane et al
have published the results of a quality-of-life assessment
in NHD [73].
Because of the adverse patient outcomes associated
with conventional hemodialysis, it is understandable that
NHD has been greeted with enthusiasm by nephrolo-
gists. However, no published trial of NHD has used a
randomized design, and observational studies have well-
known limitations. Although randomized trials are rel-
atively infrequent in dialysis populations [74, 75], we
believe that such a study is required before NHD can
be widely recommended, especially given the substantial
cost and time associated with the initiation of an NHD
program. Although a randomized study that was pow-
ered for a clinically relevant difference in mortality would
probably require thousands of patients, our data suggest
that markedly fewer subjects would be required to prop-
erly evaluate the effect of NHD on continuous outcomes.
For example, to detect a 20% reduction in magnetic
resonance measured left ventricular mass due to NHD
(similar to the effect size reported by Chan et al [60]), a
randomized study would achieve 90% power with 18 sub-
jects per arm, assuming no change in subjects receiving
conventional hemodialysis and a 15% drop-out rate due
to transplantation. While it could be argued that a ran-
domized trial of NHD would pose ethical issues, given
that it is increasingly being offered as routine therapy,
we believe that this highlights the need to conduct such
a study so that NHD is not established as the standard of
care without appropriate evaluation.
CONCLUSION
NHD is a potential alternative to conventional thrice-
weekly hemodialysis. The fundamental concept of a more
“physiologic” dialysis has appeal, and today’s dialysis
technology is making this approach more feasible. How-
ever, current data are incomplete and have potentially
serious methodologic limitations. Given the potential
bias noted within existing research, a randomized clinical
trial comparing nocturnal hemodialysis to conventional
thrice-weekly hemodialysis is needed.
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